Description
GBR-12909 is a potent and selective dopamine reuptake inhibitor (DRI). In a mouse model it has been found to increase activity and reduce spatial d in combination with increased exploratory behavior.
| Product Unit Size | Cost | Quantity | Stock |
|---|
GBR-12909 is a potent and selective dopamine reuptake inhibitor (DRI). In a mouse model it has been found to increase activity and reduce spatial d in combination with increased exploratory behavior.
| Cas No. | 67469-78-7 |
|---|---|
| Purity | ≥98% |
| Formula | C28H32F2N2O • 2HCl |
| Formula Wt. | 523.49 |
| Chemical Name | 1-(2-(bis(4-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazine dihydrochloride |
| IUPAC Name | 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine;dihydrochloride |
| Synonym | Vanorexine Dihydrochloride, Vanoxerine hydrochloride |
| Solubility | Slightly soluble in water ~2.5 mg/mL. Solubility in DMSO - >25 mg/mL. |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Andersen P. The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action. Eur J Pharmacol. 166(3):493-504 (1989). PMID: 2530094.
Young J, Goey A, Minassian A, et al. GBR 12909 administration as a mouse model of bipolar disorder mania: mimicking quantitative assessment of manic behavior. Psychopharmacology (Berl). 2010 Feb;208(3):443-454. PMID: 20020109.
Nucleoside (guanosine) analog; DNA chain termin...
Flavanol originally found in Camilla (green tea...
Selective inhibitor of protein kinase C (PKC).<...
PKC activator, carcinogen.
Quinolone, antioxidant.
Steroid lactone produced by Withania somnifera;...
JAK3 inhibitor.
Kavalactone originally found in Piper methystic...
Prevents MHC II antigen presentation.
PP2A inhibitor.
Natriuretic, vasodilatory peptide; B1/2 agonist...
Epoxide metabolite of acrylamide, induces DNA a...
Benzophenanthridine alkaloid; topoisomerase I i...
Synthetic peptide hormone.
B-Raf and c-Raf inhibitor.
Non-fluorescent halogenated A23187 analog, Ca2+...
Caspase 9 substrate.
Glucocorticoid
PARP inhibitor; potential Pim1 inhibitor.
FLT3, c-Kit, PDGFR inhibitor.